Author:
Amir Eitan,Ocaña Alberto,Seruga Bostjan,Josse Robert,Clemons Mark
Publisher
Springer Science and Business Media LLC
Reference10 articles.
1. Howell, A. et al. Results of the ATAC (Arimidex, Tamoxifen, Alone or in Combination) trial after completion of 5 years' adjuvant treatment for breast cancer. Lancet 365, 60–62 (2005).
2. Brufsky, A. M. et al. Zoledronic acid effectively prevents aromatase inhibitor-associated bone loss in postmenopausal women with early breast cancer receiving adjuvant letrozole: Z.-FAST study 36-month follow-up results. Clin. Breast Cancer 9, 77–85 (2009).
3. Eidtmann, H. et al. The effect of zoledronic acid on aromatase inhibitor associated bone loss in postmenopausal women with early breast cancer receiving adjuvant letrozole: 36 months follow-up of ZO-FAST. Cancer Res. 69, 74S (American Association for Cancer Research, 2009).
4. Lombarto, A. et al. Effect of zoledronic acid on aromatase inhibitor-associated bone loss in postmenopausal women with early breast cancer receiving adjuvant letrozole: E-ZO-FAST 36-month follow up. Proc. American Soc. Clinical Oncology 213 (American Society of Clinical Oncology, 2009).
5. Seeman, E. Is a change in bone mineral density a sensitive and specific surrogate of anti-fracture efficacy? Bone 4 1, 308–317 (2007).
Cited by
11 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献